Skip to content
2000
Volume 22, Issue 5
  • ISSN: 1573-3998
  • E-ISSN: 1875-6417
file format pdf download PDF
file format text download EPUB
side by side viewer icon HTML

Abstract

Insulin resistance is an endocrine disorder associated with various diseases, including diabetes, metabolic syndrome, cardiovascular diseases, and cancer. However, severe insulin resistance differs significantly from common insulin resistance regarding the causes and treatment approaches. Severe insulin resistance is a group of rare disorders characterized by hyperglycemia and hyperinsulinemia, with or without hypoglycemia, along with various metabolic abnormalities and diverse clinical manifestations. Owing to their rarity and complexity, these conditions can be easily misdiagnosed as common diabetes and are often overlooked. Severe insulin resistance is typically reported in individual case studies, lacking comprehensive summaries. This article provides a detailed overview of the different types of severe insulin resistance based on the specific sites of insulin signaling defects. It includes pre-receptor signaling defects, such as insulin autoimmune syndrome, which results from insulin autoantibodies; receptor-level insulin resistance syndromes, including type A and type B insulin resistance syndromes; and post-receptor signaling defects, such as lipodystrophy syndrome. We describe the causes, clinical symptoms, diagnosis, and treatment of extreme insulin resistance and differentiate between these diseases. In this review, we aim to assist physicians in identifying the causes of severe insulin resistance early and in providing individualized treatment for patients, ultimately improving clinical outcomes.

© 2026 The Author(s). Published by Bentham Science Publishers.
This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode
Loading

Article metrics loading...

/content/journals/cdr/10.2174/0115733998390048250902113845
2025-09-17
2026-04-17

  • From This Site

    /content/journals/cdr/10.2174/0115733998390048250902113845
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/cdr/22/5/CDR-22-5-04.html?itemId=/content/journals/cdr/10.2174/0115733998390048250902113845&mimeType=html&fmt=ahah

References

  1. GallagherE.J. LeRoithD. Hyperinsulinaemia in cancer.Nat. Rev. Cancer2020201162964410.1038/s41568‑020‑0295‑532908223
     [Google Scholar]
  2. SamuelV.T. ShulmanG.I. Mechanisms for insulin resistance: Common threads and missing links.Cell2012148585287110.1016/j.cell.2012.02.01722385956
     [Google Scholar]
  3. HillM.A. YangY. ZhangL. SunZ. JiaG. ParrishA.R. SowersJ.R. Insulin resistance, cardiovascular stiffening and cardiovascular disease.Metabolism202111915476610.1016/j.metabol.2021.15476633766485
     [Google Scholar]
  4. SaltielA.R. Insulin signaling in health and disease.J. Clin. Invest.2021131114224110.1172/JCI14224133393497
     [Google Scholar]
  5. KosmasC.E. BousvarouM.D. KostaraC.E. PapakonstantinouE.J. SalamouE. GuzmanE. Insulin resistance and cardiovascular disease.J. Int. Med. Res.20235130300060523116454810.1177/0300060523116454836994866
     [Google Scholar]
  6. LiM. ChiX. WangY. SetrerrahmaneS. XieW. XuH. Trends in insulin resistance: Insights into mechanisms and therapeutic strategy.Signal Transduct. Target. Ther.20227121610.1038/s41392‑022‑01073‑035794109
     [Google Scholar]
  7. ZhouQ. YuJ. YuanX. WangC. ZhuZ. ZhangA. GuW. Clinical and functional characterization of novel INSR variants in two families with severe insulin resistance syndrome.Front. Endocrinol.20211260696410.3389/fendo.2021.60696433995269
     [Google Scholar]
  8. SongY. LeiW. HuangQ. ZhangJ. ZhangQ. ChenL. LiH. LiuL. ZengT. HuX. A new heterozygous variant of c.1225_1227delTTC (p.Phe409del) in insulin receptor gene associated with severe insulin resistance and hyperandrogenemia in an adolescent female with type a severe insulin resistance syndrome.Diabetes Metab. Syndr. Obes.2024174389439610.2147/DMSO.S48174539619220
     [Google Scholar]
  9. HovelroudR Goh Xiu MingS McLeodDSA DonovanPJ NgG MungomeryM A case of enfortumab vedotin-associated diabetic ketoacidosis with severe insulin resistance in a nondiabetic woman.JCEM Case Rep2024212luae21210.1210/jcemcr/luae21239588551
     [Google Scholar]
  10. PlaczkowskaS. Pawlik-SobeckaL. KokotI. PiwowarA. Indirect insulin resistance detection: Current clinical trends and laboratory limitations.Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub.2019163318719910.5507/bp.2019.02131165793
     [Google Scholar]
  11. TahaparyD.L. PratisthitaL.B. FitriN.A. MarcellaC. WafaS. KurniawanF. RizkaA. TariganT.J.E. HarbuwonoD.S. PurnamasariD. SoewondoP. Challenges in the diagnosis of insulin resistance: Focusing on the role of HOMA-IR and Tryglyceride/glucose index.Diabetes Metab. Syndr.202216810258110.1016/j.dsx.2022.10258135939943
     [Google Scholar]
  12. GastaldelliA. Measuring and estimating insulin resistance in clinical and research settings.Obesity20223081549156310.1002/oby.2350335894085
     [Google Scholar]
  13. Standards of medical care in diabetes—2019 abridged for primary care providers.Clin. Diabetes2019371113410.2337/cd18‑010530705493
     [Google Scholar]
  14. AngelidiA.M. FilippaiosA. MantzorosC.S. Severe insulin resistance syndromes.J. Clin. Invest.2021131414224510.1172/JCI14224533586681
     [Google Scholar]
  15. González-SaldivarG. Rodríguez-GutiérrezR. Ocampo-CandianiJ. González-GonzálezJ.G. Gómez-FloresM. Skin manifestations of insulin resistance: From a biochemical stance to a clinical diagnosis and management.Dermatol. Ther.201771375110.1007/s13555‑016‑0160‑327921251
     [Google Scholar]
  16. DingH. ZhangJ. ZhangF. ZhangS. ChenX. LiangW. XieQ. Resistance to the insulin and elevated level of androgen: A major cause of polycystic ovary syndrome.Front. Endocrinol.20211274176410.3389/fendo.2021.74176434745009
     [Google Scholar]
  17. KampmannU. KnorrS. FuglsangJ. OvesenP. Determinants of maternal insulin resistance during pregnancy: An updated overview.J. Diabetes Res.201920191910.1155/2019/532015631828161
     [Google Scholar]
  18. GuoX. AsthanaP. GurungS. ZhangS. WongS.K.K. FallahS. ChowC.F.W. CheS. ZhaiL. WangZ. GeX. JiangZ. WuJ. ZhangY. WuX. XuK. LinC.Y. KwanH.Y. LyuA. ZhouZ. BianZ.X. WongH.L.X. Regulation of age-associated insulin resistance by MT1-MMP-mediated cleavage of insulin receptor.Nat. Commun.2022131374910.1038/s41467‑022‑31563‑235768470
     [Google Scholar]
  19. JamesD.E. StöckliJ. BirnbaumM.J. The aetiology and molecular landscape of insulin resistance.Nat. Rev. Mol. Cell Biol.2021221175177110.1038/s41580‑021‑00390‑634285405
     [Google Scholar]
  20. FèveB. ScheenA.J. When therapeutic drugs lead to diabetes.Diabetologia202265575176210.1007/s00125‑022‑05666‑w35244742
     [Google Scholar]
  21. IsmailA.A.A. The insulin autoimmune syndrome (IAS) as a cause of hypoglycaemia: An update on the pathophysiology, biochemical investigations and diagnosis.Clinical Chemistry and Laboratory Medicine (CCLM)201654111715172410.1515/cclm‑2015‑125527071154
     [Google Scholar]
  22. CryerP.E. AxelrodL. GrossmanA.B. HellerS.R. MontoriV.M. SeaquistE.R. ServiceF.J. Evaluation and management of adult hypoglycemic disorders: An Endocrine Society Clinical Practice Guideline.J. Clin. Endocrinol. Metab.200994370972810.1210/jc.2008‑141019088155
     [Google Scholar]
  23. HattoriN. DuhitaM.R. MukaiA. MatsuedaM. ShimatsuA. Development of insulin antibodies and changes in titers over a long-term period in patients with type 2 diabetes.Clin. Chim. Acta201443313513810.1016/j.cca.2014.03.00824642342
     [Google Scholar]
  24. ZhangP. JiangQ. DingB. YanR.N. HuY. MaJ.H. Association between glucose-lowering drugs and circulating insulin antibodies induced by insulin therapy in patients with type 2 diabetes.World J. Diabetes20241571489149810.4239/wjd.v15.i7.148939099829
     [Google Scholar]
  25. VoraJ. SeufertJ. SolbergH. KinduryteO. JohansenT. HollanderP. Insulin degludec does not increase antibody formation versus insulin glargine: An evaluation of phase IIIa trials.Diabetes Obes. Metab.201618771672010.1111/dom.1262126663320
     [Google Scholar]
  26. AhmedM. SubbalaxmiM.V.S. AnneB. DemeS. Recurrent diabetic ketoacidosis and extreme insulin resistance due to anti-insulin antibodies: Response to immunosuppression and plasma exchange.Diabetes Technol. Ther.202123322722910.1089/dia.2020.043833016111
     [Google Scholar]
  27. LiuH. LiangS. LiY. FuJ. ChenS. LiM. ZhuH. PanH. WangO. YuanT. MaoJ. QinY. LiY. A novel type of extreme insulin resistance: Nonhypoglycemic insulin autoimmune syndrome.J. Clin. Endocrinol. Metab.20211064e1051e106110.1210/clinem/dgaa91133382420
     [Google Scholar]
  28. VirallyM.L. TimsitJ. ChansonP. WarnetA. GuillausseauP.J. Insulin autoimmune syndrome: A rare cause of hypoglycaemia not to be overlooked.Diabetes Metab.199925542943110592867
     [Google Scholar]
  29. HirataY. IshizuH. OuchiN. Insulin autoimmunity in a case of spontaneous hypoglycemia.J Jpn Diabetes Soc.19701331232010.11213/tonyobyo1958.13.312
     [Google Scholar]
  30. CensiS. MianC. BetterleC. Insulin autoimmune syndrome: From diagnosis to clinical management.Ann. Transl. Med.201861733510.21037/atm.2018.07.3230306074
     [Google Scholar]
  31. ShenY. SongX. RenY. Insulin autoimmune syndrome induced by exogenous insulin injection: A four-case series.BMC Endocr. Disord.201919114810.1186/s12902‑019‑0482‑031883520
     [Google Scholar]
  32. XuL.L. ChenJ.X. ChengJ.P. LuoN. Exogenous insulin autoimmune syndrome: A case report and review of literature.World J. Clin. Cases20241291691169710.12998/wjcc.v12.i9.169138576740
     [Google Scholar]
  33. IshizukaT. OgawaS. MoriT. NakoK. NakamichiT. OkaY. ItoS. Characteristics of the antibodies of two patients who developed daytime hyperglycemia and morning hypoglycemia because of insulin antibodies.Diabetes Res. Clin. Pract.2009842e21e2310.1016/j.diabres.2009.02.00719328577
     [Google Scholar]
  34. JerkinsT. BellD.S.H. Development of exogenous insulin antibody syndrome in a patient with newly diagnosed type 1 diabetes successfully treated with oral immunosuppressive monotherapy.Diabetes Ther.202112102795279910.1007/s13300‑021‑01129‑434403116
     [Google Scholar]
  35. SharwoodE.F. HughesI.P. PretoriusC.J. TrnkaP. PeakeJ. HuynhT. Therapeutic plasma exchange normalizes insulin-mediated response in a child with type 1 diabetes and insulin autoimmune syndrome.Pediatr. Diabetes201819117117910.1111/pedi.1252228370959
     [Google Scholar]
  36. ShenY. PrinyawiwatkulW. XuZ. Insulin: A review of analytical methods.Analyst2019144144139414810.1039/C9AN00112C31143899
     [Google Scholar]
  37. HuynhT. Clinical and laboratory aspects of insulin autoantibody-mediated glycaemic dysregulation and hyperinsulinaemic hypoglycaemia: Insulin autoimmune syndrome and exogenous insulin antibody syndrome.Clin. Biochem. Rev.20204139310210.33176/AACB‑20‑0000833343044
     [Google Scholar]
  38. QuanH. TanH. LiQ. LiJ. LiS. Immunological hypoglycemia associated with insulin antibodies induced by exogenous insulin in 11 Chinese patients with diabetes.J. Diabetes Res.201520151910.1155/2015/74627125961056
     [Google Scholar]
  39. UrsiniF. RussoE. PellinoG. D’AngeloS. ChiaravallotiA. De SarroG. ManfrediniR. De GiorgioR. Metformin and autoimmunity: a “new deal” of an old drug.Front. Immunol.20189123610.3389/fimmu.2018.0123629915588
     [Google Scholar]
  40. PanikarV. JoshiS. VadgamaJ. KamatT. WagleT. NasilkarN. ShahN. SheikhS. JainC. Autoimmune hypoglycemia relapse on glucocorticoids, effectively treated with azathioprine.J. Assoc. Physicians India20186612787931313558
     [Google Scholar]
  41. ChurchD. HunterR.W. LyallM. ClarkeC. VliegenthartA.D.B. DearJ.W. SempleR. DhaunN. DoverA.R. Resolution of hypoglycemia and cardiovascular dysfunction after rituximab treatment of insulin autoimmune syndrome.Diabetes Care2017407e80e8210.2337/dc17‑026428461453
     [Google Scholar]
  42. YuL. HeroldK. Krause-SteinraufH. McGeeP.L. BundyB. PuglieseA. KrischerJ. EisenbarthG.S. Rituximab selectively suppresses specific islet antibodies.Diabetes201160102560256510.2337/db11‑067421831969
     [Google Scholar]
  43. QinL. LiX. HouQ. WangH. LouG. LiT. WangL. LiuH. LiX. LiaoS. Novel heterozygous mutations of the INSR gene in a familial case of Donohue syndrome.Clin. Chim. Acta2017473263110.1016/j.cca.2017.08.00728803747
     [Google Scholar]
  44. Ariza JiménezA.B. López SigueroJ.P. Martínez Aedo OlleroM.J. Del Pino de la FuenteA. Isabel Leiva Gea INSR gene mutation. Insulin resistance with low prevalence in pediatrics. A case review.Endocrinol. Diabetes Nutr.201966958858910.1016/j.endien.2019.04.00431229400
     [Google Scholar]
  45. OgawaW. ArakiE. IshigakiY. HirotaY. MaegawaH. YamauchiT. YorifujiT. KatagiriH. New classification and diagnostic criteria for insulin resistance syndrome.Endocr. J.202269210711310.1507/endocrj.EJ21‑072535110500
     [Google Scholar]
  46. VambergueA. LautierC. ValatA.S. Cortet-RudelliC. GrigorescuF. DewaillyD. Follow-up study of two sisters with type A syndrome of severe insulin resistance gives a new insight into PCOS pathogenesis in relation to puberty and pregnancy outcome: A case report.Hum. Reprod.20062151274127810.1093/humrep/dei45516410336
     [Google Scholar]
  47. FourmanL.T. TsaiL.L. BrownR.J. O’RahillyS. Case 10-2024: A 46-year-old woman with hyperglycemia refractory to insulin therapy.N. Engl. J. Med.2024390131219122910.1056/NEJMcpc231272938598578
     [Google Scholar]
  48. IwanishiM. KusakabeT. AzumaC. TezukaY. YamamotoY. Ito-KobayashiJ. WashiyamaM. MorimotoM. EbiharaK. Clinical characteristics in two patients with partial lipodystrophy and Type A insulin resistance syndrome due to a novel heterozygous missense mutation in the insulin receptor gene.Diabetes Res. Clin. Pract.2019152798710.1016/j.diabres.2019.04.03431102683
     [Google Scholar]
  49. TakasawaK. Tsuji-HosokawaA. TakishimaS. WadaY. NagasakiK. DatekiS. NumakuraC. HijikataA. ShiraiT. KashimadaK. MorioT. Clinical characteristics of adolescent cases with Type A insulin resistance syndrome caused by heterozygous mutations in the β-subunit of the insulin receptor ( INSR ) gene.J. Diabetes2019111465410.1111/1753‑0407.1279729877041
     [Google Scholar]
  50. SempleR.K. WilliamsR.M. DungerD.B. Clinical question: What is the best management strategy for patients with severe insulin resistance?Clin. Endocrinol.201073328629010.1111/j.1365‑2265.2010.03810.x20455892
     [Google Scholar]
  51. LinL. ChenC. FangT. ChenD. ChenK. QuanH. Type A insulin resistance syndrome misdiagnosed as polycystic ovary syndrome: A case report.J. Med. Case Rep.201913134710.1186/s13256‑019‑2304‑431771632
     [Google Scholar]
  52. ZhuL.Y. MaT.S. LiX.J. ChangX.Y. SunK. ZhangH.B. LiY. A case of type A insulin resistance syndrome.Zhonghua Nei Ke Za Zhi202261111253125610.3760/cma.j.cn112138‑20211208‑0087036323568
     [Google Scholar]
  53. ChenY.H. ChenQ.Q. WangC.L. Treatment and five-year follow-up of type A insulin resistance syndrome: A case report.World J. Clin. Cases20221082522252810.12998/wjcc.v10.i8.252235434067
     [Google Scholar]
  54. KocaS.B. KulaliM.A. GüğüşB. DemirbilekH. Type A insulin resistance syndrome due to a novel heterozygous c.3486_3503del (p. Arg1163_Ala1168del) INSR gene mutation in an adolescent girl and her mother.Arch. Endocrinol. Metab.20246821030510.20945/2359‑4292‑2021‑030538289143
     [Google Scholar]
  55. HuangZ. LiuJ. NgK. WanX. XuL. HeX. LiaoZ. LiY. Glimepiride treatment in a patient with type A insulin resistance syndrome due to a novel heterozygous missense mutation in the insulin receptor gene.J. Diabetes Investig.2018951075108310.1111/jdi.1282429469970
     [Google Scholar]
  56. NagashimaS. WakabayashiT. SaitoN. TakahashiM. OkadaK. EbiharaK. IshibashiS. Long-term efficacy of the sodium–glucose cotransporter 2 inhibitor, ipragliflozin, in a case of type A insulin resistance syndrome.J. Diabetes Investig.20201151363136510.1111/jdi.1324132100949
     [Google Scholar]
  57. Martínez-MontoroJ.I. Pinzón-MartínJ.L. Damas-FuentesM. Fernández-ValeroA. TinahonesF.J. Combination therapy with semaglutide and dapagliflozin as an effective approach for the management of type a insulin resistance syndrome: A case report.Front. Endocrinol.20221383888710.3389/fendo.2022.83888735498407
     [Google Scholar]
  58. McDonaldA. WilliamsR.M. ReganF.M. SempleR.K. DungerD.B. IGF-I treatment of insulin resistance.Eur. J. Endocrinol.2007157Suppl. 1S51S5610.1530/EJE‑07‑027117785698
     [Google Scholar]
  59. ReganF.M. WilliamsR.M. McDonaldA. UmplebyA.M. AceriniC.L. O’RahillyS. HovorkaR. SempleR.K. DungerD.B. Treatment with recombinant human insulin-like growth factor (rhIGF)-I/rhIGF binding protein-3 complex improves metabolic control in subjects with severe insulin resistance.J. Clin. Endocrinol. Metab.20109552113212210.1210/jc.2009‑208820233784
     [Google Scholar]
  60. OkamotoH. CavinoK. NaE. KrummE. KimS.Y. ChengX. MurphyA.J. YancopoulosG.D. GromadaJ. Glucagon receptor inhibition normalizes blood glucose in severe insulin-resistant mice.Proc. Natl. Acad. Sci. USA2017114102753275810.1073/pnas.162106911428115707
     [Google Scholar]
  61. BrownR.J. CochranE. GordenP. Metreleptin improves blood glucose in patients with insulin receptor mutations.J. Clin. Endocrinol. Metab.20139811E1749E175610.1210/jc.2013‑231723969187
     [Google Scholar]
  62. FlierJ.S. KahnC.R. RothJ. BarR.S. Antibodies that impair insulin receptor binding in an unusual diabetic syndrome with severe insulin resistance.Science19751904209636510.1126/science.170678170678
     [Google Scholar]
  63. Klubo-GwiezdzinskaJ. LangeM. CochranE. SempleR.K. GewertC. BrownR.J. GordenP. Combined immunosuppressive therapy induces remission in patients with severe type B insulin resistance: A prospective cohort study.Diabetes Care201841112353236010.2337/dc18‑088430201849
     [Google Scholar]
  64. MartinsL.M. FernandesV.O. CarvalhoM.M.D. GadelhaD.D. QueirozP.C. MontenegroR.M. Type B insulin resistance syndrome: A systematic review.Arch. Endocrinol. Metab.202064433734810.20945/2359‑399700000025732813762
     [Google Scholar]
  65. BrownN. ElstonM.S. Systematic review—Type B Insulin resistance with isolated hypoglycemia and suppressed insulin.J. Clin. Endocrinol. Metab.2024109493694310.1210/clinem/dgad46737552775
     [Google Scholar]
  66. HirotaY. SuwanaiH. YamauchiT. KadowakiT. Clinical features of type B insulin resistance in Japanese patients: Case report and survey-based case series study.J. Diabetes Res.2020202011110.1155/2020/435978732337291
     [Google Scholar]
  67. ŁebkowskaA. KrentowskaA. AdamskaA. LipińskaD. PiaseckaB. Kowal-BieleckaO. GórskaM. SempleR.K. KowalskaI. Type B insulin resistance syndrome associated with connective tissue disease and psoriasis.Endocrinol. Diabetes Metab. Case Rep.20202020EDM20002710.1530/EDM‑20‑002732755965
     [Google Scholar]
  68. SjöholmÅ. PereiraM.J. NilssonT. LindeT. KatsogiannosP. SaafJ. ErikssonJ.W. Type B insulin resistance syndrome in a patient with type 1 diabetes.Endocrinol. Diabetes Metab. Case Rep.2020202019015710.1530/EDM‑19‑015732478674
     [Google Scholar]
  69. AriogluE. AndeweltA. DiaboC. BellM. TaylorS. GordenP. Clinical course of the syndrome of autoantibodies to the insulin receptor (type B insulin resistance): A 28-year perspective.Medicine20028128710010.1097/00005792‑200203000‑0000111889410
     [Google Scholar]
  70. MinichW.B. AbelB.S. SchwiebertC. WelsinkT. SeemannP. BrownR.J. SchomburgL. A novel in vitro assay correlates insulin receptor autoantibodies with fasting insulin in type B insulin resistance.J. Clin. Endocrinol. Metab.202310892324232910.1210/clinem/dgad12536869714
     [Google Scholar]
  71. CollA.P. ThomasS. MuftiG.J. Rituximab therapy for the type B syndrome of severe insulin resistance.N. Engl. J. Med.2004350331031110.1056/NEJM20040115350032414724317
     [Google Scholar]
  72. TakeiM. IshiiH. KawaiY. KatoK. SekidoT. SatoY. TakedaT. KomatsuM. Efficacy of oral glucocorticoid and cyclosporine in a case of rituximab-refractory type B insulin resistance syndrome.J. Diabetes Investig.20156673473810.1111/jdi.1233726543549
     [Google Scholar]
  73. ZhaoL. LiW. LiuL. DuanL. WangL. YangH. ZhangH. LiY. Clinical features and outcome analysis of type B insulin resistance syndrome: A single-center study in China.J. Clin. Endocrinol. Metab.20231091e175e18110.1210/clinem/dgad46137536271
     [Google Scholar]
  74. SantosM.L.C. BritoB.B. SilvaF.A.F. SampaioM.M. MarquesH.S. SilvaN.O. QueirozD.M.M. MeloF.F. Helicobacter pylori infection: Beyond gastric manifestations.World J. Gastroenterol.202026284076409310.3748/wjg.v26.i28.407632821071
     [Google Scholar]
  75. YangG.Q. LiY.J. DouJ.T. WangB.A. LuJ.M. MuY.M. Type B insulin resistance syndrome with Scleroderma successfully treated with multiple immune suppressants after eradication of Helicobacter pylori infection: A case report.BMC Endocr. Disord.20161612010.1186/s12902‑016‑0099‑527142369
     [Google Scholar]
  76. KawasakiF. AnnoT. TakaiM. IrieS. KanetoH. KakuK. OkimotoN. Saibokuto as a possible therapy for type B insulin resistance syndrome: The disappearance of anti-insulin receptor antibody and a marked amelioration of glycemic control by saibokuto treatment.Intern. Med.201857162359236310.2169/internalmedicine.0523‑1729526960
     [Google Scholar]
  77. HussainI. GargA. Lipodystrophy Syndromes.Endocrinol. Metab. Clin. North Am.201645478379710.1016/j.ecl.2016.06.01227823605
     [Google Scholar]
  78. MannJ.P. SavageD.B. What lipodystrophies teach us about the metabolic syndrome.J. Clin. Invest.2019129104009402110.1172/JCI12919031380809
     [Google Scholar]
  79. SantosJ.L. CortésV.A. Eating behaviour in contrasting adiposity phenotypes: Monogenic obesity and congenital generalized lipodystrophy.Obes. Rev.20212211311410.1111/obr.1311433030294
     [Google Scholar]
  80. PatniN. GargA. Lipodystrophy for the diabetologist—What to look for.Curr. Diab. Rep.202222946147010.1007/s11892‑022‑01485‑w35821558
     [Google Scholar]
  81. MisraA. GargA. Clinical features and metabolic derangements in acquired generalized lipodystrophy: Case reports and review of the literature.Medicine200382212914610.1097/00005792‑200303000‑0000712640189
     [Google Scholar]
  82. OliveiraJ. FreitasP. LauE. CarvalhoD. Barraquer–Simons syndrome: A rare form of acquired lipodystrophy.BMC Res. Notes20169117510.1186/s13104‑016‑1975‑926987365
     [Google Scholar]
  83. BagiasC. XiarchouA. BargiotaA. TigasS. Familial partial lipodystrophy (FPLD): Recent insights.Diabetes Metab. Syndr. Obes.2020131531154410.2147/DMSO.S20605332440182
     [Google Scholar]
  84. FourmanL.T. GrinspoonS.K. Approach to the patient with lipodystrophy.J. Clin. Endocrinol. Metab.202210761714172610.1210/clinem/dgac07935137140
     [Google Scholar]
  85. SempleR.K. HalbergN.H. BurlingK. SoosM.A. SchrawT. LuanJ. CochranE.K. DungerD.B. WarehamN.J. SchererP.E. GordenP. O’RahillyS. Paradoxical elevation of high-molecular weight adiponectin in acquired extreme insulin resistance due to insulin receptor antibodies.Diabetes20075661712171710.2337/db06‑166517325257
     [Google Scholar]
  86. BrownR.J. Araujo-VilarD. CheungP.T. DungerD. GargA. JackM. MungaiL. OralE.A. PatniN. RotherK.I. von SchnurbeinJ. SorkinaE. StanleyT. VigourouxC. WabitschM. WilliamsR. YorifujiT. The diagnosis and management of lipodystrophy syndromes: A multi-society practice guideline.J. Clin. Endocrinol. Metab.2016101124500451110.1210/jc.2016‑246627710244
     [Google Scholar]
  87. RoumaneA. McilroyG.D. SommerN. HanW. HeislerL.K. RochfordJ.J. GLP-1 receptor agonist improves metabolic disease in a pre-clinical model of lipodystrophy.Front. Endocrinol.202415137922810.3389/fendo.2024.137922838745956
     [Google Scholar]
  88. Foss-FreitasM.C. ImamS. NeidertA. GomesA.D. BroomeD.T. OralE.A. Efficacy and safety of glucagon-like peptide 1 agonists in a retrospective study of patients with familial partial lipodystrophy.Diabetes Care202447465365910.2337/dc23‑161438300898
     [Google Scholar]
  89. HamaguchiT. HirotaY. TakeuchiT. NakagawaY. MatsuokaA. MatsumotoM. AwanoH. IijimaK. ChaP.C. SatakeW. TodaT. OgawaW. Treatment of a case of severe insulin resistance as a result of a PIK 3R1 mutation with a sodium–glucose cotransporter 2 inhibitor.J. Diabetes Investig.2018951224122710.1111/jdi.1282529476696
     [Google Scholar]
  90. LuedtkeA. BoschmannM. ColpeC. EngeliS. AdamsF. BirkenfeldA. HaufeS. RahnG. LuftF. SchmidtH. JordanJ. Thiazolidinedione response in familial lipodystrophy patients with LMNA mutations: A case series.Horm. Metab. Res.201244430631110.1055/s‑0031‑130128422274718
     [Google Scholar]
  91. SimhaV. RaoS. GargA. Prolonged thiazolidinedione therapy does not reverse fat loss in patients with familial partial lipodystrophy, Dunnigan variety.Diabetes Obes. Metab.200810121275127610.1111/j.1463‑1326.2008.00978.x19040647
     [Google Scholar]
  92. SimhaV. SubramanyamL. SzczepaniakL. QuittnerC. Adams-HuetB. SnellP. GargA. Comparison of efficacy and safety of leptin replacement therapy in moderately and severely hypoleptinemic patients with familial partial lipodystrophy of the Dunnigan variety.J. Clin. Endocrinol. Metab.201297378579210.1210/jc.2011‑222922170723
     [Google Scholar]
/content/journals/cdr/10.2174/0115733998390048250902113845
Loading
Severe Insulin Resistance: Diagnosis and Management
Curr. Diabetes Rev. 22, E15733998390048 (2026); https://doi.org/10.2174/0115733998390048250902113845
/content/journals/cdr/10.2174/0115733998390048250902113845
/content/journals/cdr/10.2174/0115733998390048250902113845
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): insulin autoantibodies; insulin autoimmune syndrome; Lipodystrophy syndrome; Severe insulin resistance; Type A insulin resistance syndrome; Type B insulin resistance syndrome

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test